219 related articles for article (PubMed ID: 15788680)
1. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Govindan R; Kratzke RA; Herndon JE; Niehans GA; Vollmer R; Watson D; Green MR; Kindler HL;
Clin Cancer Res; 2005 Mar; 11(6):2300-4. PubMed ID: 15788680
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Chen X; Darcy KM; Decesare SL; Lewandowski G; Lee RB; Arciero CA; Wu H; Godwin AK
Clin Cancer Res; 2005 Aug; 11(15):5539-48. PubMed ID: 16061871
[TBL] [Abstract][Full Text] [Related]
3. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Garland LL; Rankin C; Gandara DR; Rivkin SE; Scott KM; Nagle RB; Klein-Szanto AJ; Testa JR; Altomare DA; Borden EC
J Clin Oncol; 2007 Jun; 25(17):2406-13. PubMed ID: 17557954
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Janmaat ML; Gallegos-Ruiz MI; Rodriguez JA; Meijer GA; Vervenne WL; Richel DJ; Van Groeningen C; Giaccone G
J Clin Oncol; 2006 Apr; 24(10):1612-9. PubMed ID: 16575012
[TBL] [Abstract][Full Text] [Related]
7. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
8. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
10. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
11. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Otterson GA; Herndon JE; Watson D; Green MR; Kindler HL;
Lung Cancer; 2004 May; 44(2):251-9. PubMed ID: 15084390
[TBL] [Abstract][Full Text] [Related]
13. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
Kindler HL; Belani CP; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
Cancer; 1999 Nov; 86(10):1985-91. PubMed ID: 10570422
[TBL] [Abstract][Full Text] [Related]
14. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Moore AM; Einhorn LH; Estes D; Govindan R; Axelson J; Vinson J; Breen TE; Yu M; Hanna NH
Lung Cancer; 2006 Apr; 52(1):93-7. PubMed ID: 16488055
[TBL] [Abstract][Full Text] [Related]
17. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal V; Lind MJ; Cawkwell L
Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA
Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924
[TBL] [Abstract][Full Text] [Related]
19. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
